American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Original Article
Neuropsychopharmacology (2002) 27 1056-1070.10.1038/S0893-133X(02)00372-X

Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo-Controlled, Cross-Over Study

Lana Dépatie1,2,3 MSc, Gillian A O'Driscoll*,1,2,3 Ph.D, Anne-Lise V Holahan2 BSc, Victoria Atkinson3 RN, Joseph X Thavundayil3 MD, N Ng Ying Kin3 Ph.D and Samarthji Lal1,3 MD
1Department of Psychiatry, Quebec, Canada
2Department of Psychology, Quebec, Canada
3McGill University, Montreal, and Douglas Hospital Research Centre, Verdun, Quebec, Canada

Correspondence: Dr Gillian A O'Driscoll, *Department of Psychology, McGill University, Stewart Biological Sciences Building, 1205 Dr. Penfield Avenue, Montreal, Quebec, Canada, H3A 1B1. Tel.: (514) 398-4916; Fax: (514) 398-4896gillian@hebb.psych.mcgill.ca

ABSTRACT

We investigated the effect of nicotine on three behavioral markers of risk for schizophrenia: sustained attention (using the Continuous Performance Task (CPT)), antisaccade performance, and smooth pursuit. Smooth pursuit was investigated in two conditions, one in which attention was enhanced (monitoring target changes) and one in which attention was not enhanced (no monitoring). Patients with schizophrenia (n = 15) and controls (n = 14) were given a 14-mg nicotine patch in a double-blind, placebo-controlled, crossover design and plasma nicotine concentrations were monitored. Nicotine concentrations were similar in both groups. A Group ´ Drug interaction (p < .02) on CPT hits indicated that nicotine improved sustained attention in patients but not in controls. Nicotine significantly decreased antisaccade errors (p < .01) in both groups. A Drug ´ Monitoring condition interaction (p < .01) on pursuit gain indicated that nicotine significantly increased pursuit gain in the no-monitoring condition in patients and controls equally, but did not improve pursuit in the monitoring condition. Thus, improvement in pursuit may have been mediated via an effect on attention rather than by an effect on oculomotor function per se. In patients, the magnitude of improvement in attention on nicotine was correlated with the improvement on eye movement tasks. Thus, nicotine improves performance on both attention and oculomotor markers of risk for schizophrenia, possibly via common mechanisms.

Keywords: Nicotine; Schizophrenia; Sustained attention; Eye movements; Smooth pursuit; Antisaccade
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 2002 by the American College of Neuropsychopharmacology